| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802692601019 | 269260101 | HOLISTEN F.C.TAB 10 MG/TAB BT x 14(BLIST 2x7) | 3.15 | 3.30 | 4.55 |
| 05/2018 | 2802692601026 | 269260102 | HOLISTEN F.C.TAB 10 MG/TAB BTx 14(BLISTER 1x14) | 3.15 | 3.30 | 4.55 |
| 05/2018 | 2802692601040 | 269260104 | HOLISTEN F.C.TAB 10 MG/TAB BTx30 (BLISTER3x10) | 5.94 | 6.23 | 8.59 |
| 05/2018 | 2802692602016 | 269260201 | HOLISTEN F.C.TAB 20 MG/TAB BTx14 (BLIST 2x7) | 3.37 | 3.53 | 4.87 |
| 05/2018 | 2802692602023 | 269260202 | HOLISTEN F.C.TAB 20 MG/TAB BTx14 (BLISTER 1x14) | 3.37 | 3.53 | 4.87 |
| 05/2018 | 2802692602047 | 269260204 | HOLISTEN F.C.TAB 20 MG/TAB BTx30 (BLISTER3x10) | 5.94 | 6.23 | 8.59 |
| 05/2018 | 2802692603013 | 269260301 | HOLISTEN F.C.TAB 40mg/TAB BTx14 (BLIST 2x7) | 3.36 | 3.52 | 4.85 |
May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.
Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.
Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered.
Atorvastatin is rapidly absorbed after oral administration with maximum plasma concentrations achieved in 1 to 2 hours. The absolute bioavailability of atorvastatin (parent drug) is approximately 12% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic bioavailability is due to presystemic clearance by gastrointestinal mucosa and first-pass metabolism in the liver.
14 hours, but half-life of HMG-CoA inhibitor activity is 20-30 hours due to longer-lived active metabolites
Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products.
* 381 L